Business
Results of Annual General Meeting
Results of Annual General Meeting.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 6363G\n Oxford BioDynamics PLC\n 30 March 2022\n \n \n \n 30 March 2022 \n \n \n Oxford BioDynamics Plc\n \n \n \n (\n \n \"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \n \n \n \n \n Results of Annual General Meeting\n \n \n \n \n \n Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch® 3D genomics platform, announces that all resolutions at the Company's Annual General Meeting, held earlier today, were duly passed.\n \n \n \n \n \n \n \n \n \n \n \n Oxford BioDynamics Plc\n \n \n \n \n Jon Burrows, CEO\n \n \n Paul Stockdale, CFO\n \n \n \n \n \n \n \n +44 (0)1865 518910\n \n \n \n \n \n \n Shore Capital \n \n \n Nominated Adviser and Broker\n \n \n Stephane Auton\n \n \n John More\n \n \n \n \n \n \n \n +44 (0)20 7408 4090\n \n \n \n \n \n \n Instinctif Partners\n \n \n \n Melanie Toyne-Sewell / Nathan Billis\n \n \n \n \n Tel: +44 (0)20 7457 2020\n \n \n [email protected]\n \n \n \n \n \n \n \n Notes for Editors\n \n \n About Oxford BioDynamics Plc\n \n \n Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.\n \n \n Its flagship product is \n \n EpiSwitch® CiRT\n \n (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.\n \n \n In March 2021, the Company launched its first commercial prognostic test, \n \n EpiSwitch\n \n \n ®\n \n \n \n \n \n CST\n \n (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, \n \n EpiSwitch® Explorer Array Kit\n \n . \n \n \n The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.\n \n \n Oxford BioDynamics has participated in more than 40 partnerships w...